Eylea HD Approved for RVO and Extended Dosing episode artwork

EPISODE · Dec 3, 2025 · 5 MIN

Eylea HD Approved for RVO and Extended Dosing

from Eyewire News: The Podcast · host Eyewire News

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt disease.  Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Eylea HD Approved for RVO and Extended Dosing

0:00 5:00

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 5 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on December 3, 2025.

What is this episode about?

Eylea HD gains FDA approval for a new indication and dosing schedule; Lucentis biosimilar Byooviz receives a key approval in Europe; and Belite Bio announces topline results from its global phase 3 trial evaluating its drug candidate for Stargardt...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!